文献速递免疫规划传染病防控与疫情报告

HpaA免疫优势表位肽联合CpG佐剂鼻内免疫保护小鼠抵抗幽门螺杆菌感染

Intranasal immunization with immunodominant epitope peptides derived from HpaA conjugated with CpG adjuvant protected mice against Helicobacter pylori infection.
PubMed 文献 · Vaccine · 2018-09-11

本研究在小鼠模型中探讨HpaA蛋白经皮下或鼻内免疫能否抵抗幽门螺杆菌感染。皮下注射HpaA加完全弗氏佐剂的小鼠获得保护,而鼻内HpaA加CpG佐剂的小鼠未获保护;但鼻内免疫优势表位肽加CpG佐剂可保护小鼠,且优势表位肽较次优势表位肽激发更强的Th1应答和更稳固的保护。结果提示候选抗原长度对特定免疫途径至关重要,免疫优势表位肽是鼻内疫苗的 promising 候选。

要点

  • 皮下HpaA加完全弗氏佐剂免疫的小鼠获得抗幽门螺杆菌保护。
  • 鼻内HpaA加CpG佐剂免疫的小鼠未获得保护。
  • 鼻内免疫优势表位肽加CpG佐剂可保护小鼠,且优势表位肽较次优势表位肽激发更强Th1应答和更稳固保护。

核心结论

  • 候选抗原的长度对特定免疫途径至关重要。
  • 免疫优势表位肽是经鼻接种抵抗幽门螺杆菌感染的 promising 候选。

研究设计与样本

  • 研究采用小鼠模型,比较皮下或鼻内免疫HpaA的保护效果,并进一步比较鼻内免疫免疫优势表位肽与次优势表位肽的效果。

主要发现

  • 皮下注射HpaA加完全弗氏佐剂的小鼠获得抗幽门螺杆菌感染保护,而鼻内HpaA加CpG佐剂的小鼠未获得保护。
  • 鼻内免疫优势表位肽加CpG佐剂可保护小鼠抵抗幽门螺杆菌感染。
  • 免疫优势表位肽较次优势表位肽激发更强的Th1应答,并介导更稳固的抗幽门螺杆菌感染保护。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HpaA is considered to be an effective protective antigen for vaccination against Helicobacter pylori (H. pylori) infection. Oral immunization with HpaA significantly decreases bacterial colonization in H. pylori infected mice. In this study, we investigated whether subcutaneous or intranasal immunization with HpaA could protect against H. pylori infection. Mice immunized subcutaneously with HpaA in Complete Freund's adjuvant, but not mice intranasally immunized with HpaA in CpG adjuvant acquired protection against H. pylori infection. However, intranasal immunization with immunodominant epitope peptides in CpG adjuvant protected mice against H. pylori infection, and immunodominant epitope peptides stimulated stronger Th1 responses and mediated more robust protection against H. pylori infection than subdominant ones. Our results suggest that the length of a candidate antigen is critical for particular vaccination routes, and that immunodominant epitope peptides are promising candidates for protection against H. pylori infection through nasal vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yang WC, Sun HW, Sun HQ, et al. Intranasal immunization with immunodominant epitope peptides derived from HpaA conjugated with CpG adjuvant protected mice against Helicobacter pylori infection. Vaccine. 2018. PMID: 30217524. doi:10.1016/j.vaccine.2018.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。